In melanoma studies, TIDE was found to be more accurate than other biomarkers, such as PD-L1 levels and mutant load, in the prognosis of first-line anti-PD1 or anti-CTLA4 antibody therapy (36). The gene discussed is CTLA4; the disease is melanoma.